Lord, Abbett & Co
FULC icon

Lord, Abbett & Co’s Fulcrum Therapeutics FULC Stock Holding History

Lord, Abbett & Co’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-188,651
Closed -$4.46M – 588
2022
Q1 		$4.46M Buy
188,651
+3,417
+2% +$48.4K 0.01% 557
2021
Q4 		$3.28M Sell
185,234
-1,809
-1% -$35.8K 0.01% 577
2021
Q3 		$5.28M Buy
+187,043
New +$3.54M 0.01% 592

Other funds holding FULC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co's FULC Position: Q2 2022 in Review

Lord, Abbett & Co sold out of Fulcrum Therapeutics (FULC) in Q2 2022, closing a stake of 188,651 shares — an estimated $4.46M sold.

Lord, Abbett & Co first reported a position in FULC in Q3 2021 and held it in 3 quarters. The position peaked at $5.28M in Q3 2021. 101 funds tracked by Wall St. Rank hold FULC as of Q2 2022.

  • Lord, Abbett & Co reported no remaining Fulcrum Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Lord, Abbett & Co sold 188,651 Fulcrum Therapeutics shares in Q2 2022, an estimated $4.46M.
  • Lord, Abbett & Co first reported a position in Fulcrum Therapeutics in Q3 2021 and held it in 3 quarters.
  • Lord, Abbett & Co's Fulcrum Therapeutics position peaked at $5.28M in Q3 2021.
  • 101 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2022.

Based on Lord, Abbett & Co's 13F filing for Q2 2022, filed 12 Aug 2022.